Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2012
[Clinical features and prognostic analysis of mantle cell lymphoma].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bao Wei-ying, Wang Yan, Hu Xi-mei, Li Jun-min, Shen Zhi-xiang, Zhao Wei-li
Аннотация
OBJECTIVE: To study the clinical features, therapeutic effects, survival time and prognostic factors of patents with mantle cell lymphoma (MCL).
METHODS: Clinical data of 47 MCL patients admitted from January 2002 to December 2011 were retrospectively analyzed.
RESULTS: Of all patients, median age was 58 year-old and male to female ratio was 3.3:1. Forty-two cases (89.4%) were in Ann Arbor stage III-IV, 13 cases (27.7%) with bone marrow involvement, 6 cases (12.8%) with lymphocytosis, 18 cases (38.3%) with elevated LDH, and 28 cases (59.6%) with elevated β(2)-MG. Age, bone marrow involvement, increased LDH level and treatment without rituximab were poor prognostic factors. The efficiency and complete remission rate of rituximab combined with chemotherapy were 91.4% and 48.6%, which were superior to those of CHOP regimen (41.7% and 16.7%). As compared to CHOP regimen, rituximab combined with chemotherapy induced longer progression-free survival and overall survival.
CONCLUSION: Most patients with MCL were older adults with a male predominance and usually had bone marrow involvement and poor prognosis. Rituximab combined with chemotherapy could significantly improve patient outcome.
METHODS: Clinical data of 47 MCL patients admitted from January 2002 to December 2011 were retrospectively analyzed.
RESULTS: Of all patients, median age was 58 year-old and male to female ratio was 3.3:1. Forty-two cases (89.4%) were in Ann Arbor stage III-IV, 13 cases (27.7%) with bone marrow involvement, 6 cases (12.8%) with lymphocytosis, 18 cases (38.3%) with elevated LDH, and 28 cases (59.6%) with elevated β(2)-MG. Age, bone marrow involvement, increased LDH level and treatment without rituximab were poor prognostic factors. The efficiency and complete remission rate of rituximab combined with chemotherapy were 91.4% and 48.6%, which were superior to those of CHOP regimen (41.7% and 16.7%). As compared to CHOP regimen, rituximab combined with chemotherapy induced longer progression-free survival and overall survival.
CONCLUSION: Most patients with MCL were older adults with a male predominance and usually had bone marrow involvement and poor prognosis. Rituximab combined with chemotherapy could significantly improve patient outcome.